ATRC
$29.58
AtriCure, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United ...
Recent News
AtriCure CFO Sees 12%-14% Organic Growth in 2026 as Pain Management Adoption Accelerates
AtriCure (NASDAQ:ATRC) CFO Angie Wirick outlined the company’s early expectations for 2026 growth and discussed product adoption trends across its cardiac surgery and pain management franchises during an appearance at the Citizens Life Sciences Conference. Initial 2026 outlook: 12% to 14% organic g
Will AtriCure’s (ATRC) 2026 Profitability Guidance Mark a Turning Point in Its Investment Narrative?
AtriCure reported past fourth-quarter 2025 revenue of US$140.5 million and net income of US$1.76 million, and issued 2026 guidance calling for full-year revenue of about US$600 million to US$610 million with net earnings per share between US$0.00 and US$0.04. The shift from a full-year 2025 net loss of US$11.45 million to management’s expectation of positive net income in 2026 highlights a potential turning point in the company’s path toward consistent profitability. We’ll now examine how...
GEHC Expands BARDA Collaboration With $35M Boost for AI Ultrasound
GE HealthCare expands its BARDA deal by $35M to speed AI-enabled ultrasound and next-gen imaging for trauma care and mass casualty readiness.
Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026?
OPKO Health targets 30% growth in fiscal 2026, driven by RAYALDEE sales, strategic deals and pipeline progress, despite competitive pressures and reliance risks
SSKN Stock Falls Despite Meta-Analysis Backs Excimer Laser's Efficacy
STRATA Skin Sciences plunges 8% despite new meta-analysis backing its 308 nm excimer laser with up to 85% PASI improvement in plaque psoriasis.